Intrinsic Value of S&P & Nasdaq Contact Us

Rapid Therapeutic Science Laboratories, Inc. RTSL OTC

Other OTC • Healthcare • Medical - Devices • US • USD

SharesGrow Score
16/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a Medical - Devices company in the Healthcare sector, currently trading at $0.01. It has a SharesGrow Score of 15/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $183,296 (loss), growing at -318.1%/yr. Net profit margin is 0% (thin). Gross margin is 62.5% (+40.8 pp trend).

Balance sheet: total debt is $3M with negative equity of -$3M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 0.04 (tight liquidity). Debt-to-assets is 356.2%. Total assets: $967,763.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 0/100 (Fail), Moat 50/100 (Partial), Future ?/100 (Fail), Income ?/100 (Fail).

RTSL SharesGrow Score Overview

33/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 0/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Stock Chart & Stats

Market Data
52-Week Range0.001-0.008
Volume9.5K
Avg Volume (30D)4.6K
Market Cap$52.99K
Beta (1Y)-1.80
Share Statistics
EPS (TTM)-0.01
Shares Outstanding$19.3M
IPO Date2017-06-14
Employees3
CEODonal R. Schmidt Jr.
Financial Highlights & Ratios
Gross Profit$-23.97K
EBITDA$-59.25K
Net Income$-183.3K
Operating Income$-83.23K
Total Debt$3.45M
Net Debt$3.45M
Total Assets$967.76K
Price / Earnings (P/E)-0.6
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS7534312043

Price Chart

RTSL
Rapid Therapeutic Science Laboratories, Inc.  ·  Other OTC
Healthcare • Medical - Devices
0.00 52WK RANGE 0.01
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message